Study Description
TitleMigalastat
Short titleMigalastat Beob. Stu
General Short DescriptionThe objective of the study is to generate long term data on treatment with Migalastat under "real world" conditions. The selection of patients will be based on the SmPC/Fachinformation. The treatment duration/patient will be 2 years. All patients will be followed-up by the German Fabry expert centers that are listed below.
Scientific Short DescriptionGerman observational multicenter study of patients with Fabry disease under chaperone therapy with Migalastat-HCl.
Study start16.09.2020
Investigated Disease, Health Issue
ICD-Code- E75.2 - Sonstige Sphingolipidosen
Inclusion Criteria
Age18 - 99
GenderAll
Additional Inclusion CriteriaThe objective of the study is to generate long term data on treatment with Migalastat under "real world" conditions. The selection of patients will be based on the SmPC/Fachinformation. The treatment duration/patient will be 2 years. All patients will be followed-up by the German Fabry expert centers that are listed below.
Exclusion Criteria
The objective of the study is to generate long term data on treatment with Migalastat under "real world" conditions. The selection of patients will be based on the SmPC/Fachinformation. The treatment duration/patient will be 2 years. All patients will be followed-up by the German Fabry expert centers that are listed below.
Characteristics
StudytypeNon-interventional
StudyphaseN/A